02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Lysine-specific demethylase 3A (KDM3A; JMJD1A)

Cancer INDICATION: Multiple myeloma (MM) Patient sample, cell culture and mouse studies suggest inhibiting KDM3A could help treat multiple myeloma (MM). In patients, MM cells had higher levels of KDM3A than normal plasma cells. In...
07:00 , Apr 4, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Jumonji domain containing 1A (JMJD1A; TSGA) Mouse and cell culture studies suggest inhibiting JMJD1A could help circumvent resistance to antiangiogenic...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes; obesity Jumonji domain containing 1A (JMJD1A; JHDM2A) A study in mice suggests that targeting JMJD1A could help treat type...